Pharma
Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated
Shots: Immunocore to receive $100M upfront plus milestone payment and has an option to license IMC-C103C or grant its full rights to Genentech. If not exercised option to license, Immunocore […]readmore